Collectively, this mechanistic work provides strong support for specifically targeting the ECM stiffness-S100A4-NMII-A axis to halt fibrosis progression in IPF, and potentially a number of other fibrotic and malignant disorders. Here, S100A4 is linked to idiopathic pulmonary fibrosis.